TY - JOUR
T1 - Convective Radio Frequency Thermal Therapy for Treatment of Benign Prostatic Hyperplasia
T2 - Single Office Experience with 255 Patients over 4 Years
AU - Mooney, Ryan
AU - Goldberg, Kenneth
AU - Wong, Daniel
AU - Roehrborny, Claus
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Introduction: Convective radio frequency thermal therapy with the Rezum system is a relatively new treatment for benign prostatic hyperplasia with proven short-term durability. We report an update of previously published data from a single center showing durability through 4 years. Methods: A retrospective review of 255 patients who underwent the Rezum procedure from a single surgeon was performed, including 25 patients from the Rezum II study, from March 2014 to April 2018. Maximum urinary flow rate, I-PSS (International Prostate Symptom Score), I-PSSQOL (quality of life), post-void residual, medication use and adverse events were monitored. Data were analyzed at baseline, and 3, 6, 12, 24, 36 and 48 months after treatment. Results: Statistically significant improvement in maximum urinary flow rate (57.2%), I-PSS (54.7%) and I-PSS-QOL (59.2%) appear to be durable through 48 months, with improvement greater than 50% at most recent followup. We report a similarly low reoperation rate compared to the most recent data from the Rezum II study (3.1% vs 4.4%), but with higher rates of urinary tract infection (18.8% vs 3.7%) and urinary retention (15.7% vs 3.7%). Overall satisfaction with the procedure experience (93.9%) and the outcome (90.9%) was high, with 97% of men interviewed recommending the procedure to a friend. In addition, 80% of men were able to stop all medication. Conclusions: Our experience provides the largest published cohort of patients undergoing this procedure and shows durable improvements in maximum urinary flow rate, I-PSS and I-PSS-QOL through 4 years. Patients outside of the inclusion criteria of Rezum II appear to benefit from the procedure.
AB - Introduction: Convective radio frequency thermal therapy with the Rezum system is a relatively new treatment for benign prostatic hyperplasia with proven short-term durability. We report an update of previously published data from a single center showing durability through 4 years. Methods: A retrospective review of 255 patients who underwent the Rezum procedure from a single surgeon was performed, including 25 patients from the Rezum II study, from March 2014 to April 2018. Maximum urinary flow rate, I-PSS (International Prostate Symptom Score), I-PSSQOL (quality of life), post-void residual, medication use and adverse events were monitored. Data were analyzed at baseline, and 3, 6, 12, 24, 36 and 48 months after treatment. Results: Statistically significant improvement in maximum urinary flow rate (57.2%), I-PSS (54.7%) and I-PSS-QOL (59.2%) appear to be durable through 48 months, with improvement greater than 50% at most recent followup. We report a similarly low reoperation rate compared to the most recent data from the Rezum II study (3.1% vs 4.4%), but with higher rates of urinary tract infection (18.8% vs 3.7%) and urinary retention (15.7% vs 3.7%). Overall satisfaction with the procedure experience (93.9%) and the outcome (90.9%) was high, with 97% of men interviewed recommending the procedure to a friend. In addition, 80% of men were able to stop all medication. Conclusions: Our experience provides the largest published cohort of patients undergoing this procedure and shows durable improvements in maximum urinary flow rate, I-PSS and I-PSS-QOL through 4 years. Patients outside of the inclusion criteria of Rezum II appear to benefit from the procedure.
KW - Prostatic hyperplasia
KW - Radiofrequency therapy
UR - http://www.scopus.com/inward/record.url?scp=85123684628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123684628&partnerID=8YFLogxK
U2 - 10.1097/UPJ.0000000000000061
DO - 10.1097/UPJ.0000000000000061
M3 - Article
C2 - 37317411
AN - SCOPUS:85123684628
SN - 2352-0779
VL - 7
SP - 28
EP - 33
JO - Urology Practice
JF - Urology Practice
IS - 1
ER -